Abstracts tagged "rheumatoid arthritis (RA) and axial spondyloarthritis"

Abstract Number: 263 • 2019 ACR/ARP Annual Meeting
Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France
Laure Gossec¹, Anna Moltó ², Catherine Beauvais ³, Eric Senbel ⁴, René-Marc Flipo ⁵, Sophie Pouplin ⁶, Christophe Richez ⁷, Alain Saraux ⁸, Philippe Gaudin ⁹, Daniel WENDLING ¹⁰ and Maxime Dougados ¹¹, ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ³Paris St Antoine University Hospital, Paris, France, ⁴Rheumtologist Private Practice, Marseille, France, ⁵University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France, ⁶Rouen University Hospital, Rouen, France, ⁷Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ⁸CHU de la Cavale-Blanche Brest, Brest, France, ⁹Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ¹⁰Rheumatology, University Teaching Hospital (CHRU), Besançon, France, ¹¹Cochin Hospital, Paris, France
Background/Purpose: In chronic inflammatory rheumatic diseases (CIRDs), including rheumatoid arthritis, spondyloarthritis, connective tissue diseases and crystal-induced arthritis, long-term adherence to disease-modifying drugs (DMARDs) is only…
Abstract Number: 542 • 2019 ACR/ARP Annual Meeting
‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story
Carlo Selmi ¹, Klaus Krüger², Alain Cantagrel ³, Abad Hernández ⁴, Ulrich Freudensprung ⁵, Mourad Farouk Rezk ⁵ and Janet Addison ⁶, ¹Humanitas Research Hospital, University of Milan, Milan, Italy, ²Medical Centre of Rheumatology, Munich, Germany, ³Center of Rheumatology of CHU, Toulouse, France, ⁴FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁵Biogen International GmbH, Zug, Switzerland, ⁶Biogen UK, Maidenhead, United Kingdom
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].